GlaxoSmithKline and ChemoCentryx entered into license agreement to discover, develop and market drugs for treating various inflammatory diseases. The agreement also includes ChemoCentryx’s Traficet-EN®, which is in late-stage development for treating moderate-to-severe Crohn’s disease. The deal could be worth up to US$1.5635 B ChemoCentryx.